Tandem Diabetes Care, Inc. (TNDM) |
14 -0.82 (-5.53%) 10-10 16:00 |
Open: | 14.81 |
High: | 14.81 |
Low: | 13.49 |
Volume: | 1,753,283 |
Market Cap: | 946(M) |
PE Ratio: | -4.55 |
Exchange: | NASDAQ Global Market |
Industry: | Medical - Devices |
Sector: | Healthcare |
Technical analysis | ||||
![]() |
||||
sell | buy |
Resistance 2: | 18.19 |
Resistance 1: | 15.57 |
Pivot price: | 13.35 |
Support 1: | 13.03 |
Support 2: | 11.46 |
52w High: | 38.94 |
52w Low: | 9.98 |
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
EPS | -3.080 |
Book Value | 1.970 |
PEG Ratio | 0.00 |
Gross Profit | 7.790 |
Profit Margin (%) | -20.51 |
Operating Margin (%) | -13.24 |
Return on Assets (ttm) | -6.4 |
Return on Equity (ttm) | -111.9 |
Thu, 09 Oct 2025
Lobbying Update: $50,000 of TANDEM DIABETES CARE lobbying was just disclosed - Quiver Quantitative
Thu, 09 Oct 2025
TNDM Investor News: If You Have Suffered Losses in Tandem - GlobeNewswire
Wed, 08 Oct 2025
Ongoing Securities Investigation into Tandem Diabetes Care, Inc. (TNDM) - Contact Levi & Korsinsky - Newsfile
Tue, 07 Oct 2025
INVESTOR ALERT: Investigation of Tandem Diabetes Care, Inc. (TNDM) Announced by Holzer & Holzer, LLC - GlobeNewswire
Thu, 02 Oct 2025
Tandem Diabetes Care to Announce Third Quarter 2025 Financial Results on November 6, 2025 - Business Wire
Sun, 21 Sep 2025
TNDM Investors Have Opportunity to Join Tandem Diabetes Care, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
![]() StockChart iOS |
![]() StoxlineLite iOS |
![]() StoxlineLite iOS |
![]() OptionCalc iOS |
![]() StockChart Android |
![]() StoxlineLite Android |
![]() StoxlinePro Android |
![]() OptionCalc Android |